CD19 and acute lymphoblastic leukemia: Immunotherapies specific for B-cell precursor acute lymphoblastic leukemia, such as anti-CD19 chimeric antigen receptor (CAR) T-cells and blinatumomab, have dramatically improved the therapeutic outcome in refractory cases.